Apellis Pharmaceuticals, Inc.
APLS
Health Care
1
exclusion reason
1 theme
This page is part of our public exclusion list — a transparency tool that shows which companies we screen out and why. It is not investment advice, and it is not an accusation. But it is subject to change as our understanding of the facts evolves.
Apellis Pharmaceuticals develops targeted C3 complement therapies across ophthalmology, hematology, and nephrology. The company has two approved medicines: SYFOVRE (pegcetacoplan intravitreal) for geographic atrophy and EMPAVELI (pegcetacoplan subcutaneous) for paroxysmal nocturnal hemoglobinuria and, as of July 2025, for C3 glomerulopathy. Apellis is expanding into FSGS and delayed graft function with new pivotal trials, and advancing APL-90993, a gene-editing therapy developed with Beam Therapeutics targeting IND submission in late 2026. Preclinical animal testing underpins each program: pegcetacoplan was evaluated in non-human primate models for complement pathway inhibition and ocular pharmacokinetics, while new pipeline candidates require standard FDA-mandated animal toxicology and pharmacology studies.
Research Sources
1 organization
Related Exclusions
Wondering what we do invest in?
The Naughty List
A digest of changes to our exclusion list — new additions, removals, and the evidence behind them. We review the list continuously as new evidence surfaces.
Companies appear on our exclusion list based on our investment judgment — not because they've done anything illegal. This is a difference of values and opinion, not an accusation of wrongdoing. Exclusion does not constitute a recommendation against investing in any company, and absence from the list does not constitute a recommendation to invest.
This information is provided for educational and transparency purposes only and should not be relied upon as investment advice. Data is drawn from independent watchdogs, NGOs, government registries, and Ethical Capital's ongoing research — see Research Sources for the full list.
Ethical Capital LLC is a state-registered investment adviser in Utah (CRD #316032). Registration does not imply a certain level of skill or training.